Clinical biomarkers of high-density lipoprotein dysfunction among middle-aged turks;Orta yaşlı türklerde HDL disfonksiyonunun klinik markörleri

Anadolu Kardiyoloji Dergisi

Volumn 12, Issue 8, 2012, Pages 628-636

  Onat, Altan ^a   Can, Günay ^a   Murat, Sani ^b   Çiçek, Gökhan ^c   Örnek, Ender ^b   Yüksel, Hüsniye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Etlik Ihtisas Educational Hospital   (Turkey)

^c Siyami Ersek Cardiovascular Surgery Center   (Turkey)

Author keywords

C reactive protein; Coronary heart disease; Cox proportional regression analysis; Diabetes type 2; HDL dysfunction; Sensitivity; Specificity; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; HYPOALPHALIPOPROTEINEMIA; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; TURKEY (REPUBLIC); AGE; BLOOD; CORONARY ARTERY DISEASE; DIABETES MELLITUS; EVALUATION STUDY; METABOLISM; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TURKEY;

ADULT; AGE FACTORS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES; TURKEY;

EID: 84871519162     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2012.214     Document Type: Article

References (34)

1. Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008; 8: 51-59. [CrossRef]
2. Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. Curr Opin Lipidol 2010; 21: 178-185. [CrossRef]
3. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45: 993-1007. [CrossRef]
4. Hoofnagle AN, Vaisar T, Mitra P, Chait A. HDL lipids and insulin resistance. Curr Diab Rep 2010; 10: 78-86. [CrossRef]
5. Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL, Oram J F, et al. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux by the ABCA1 pathway. J Biol Chem 2010; 285: 18473-18484. [CrossRef]
6. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51: 634-642. [CrossRef]
7. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338:b92 doi:10.1136/bmj.b92. [CrossRef]
8. Giral P, Ratziu V, Couvert P, Carrié A, Kontush A, Girerd X, et al. Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. Atherosclerosis 2010; 210:607-613. [CrossRef]
9. Lim JS, Yang JH, Chun BY, Kam S, Jacobs DR Jr, Lee DH. Is serum gamma-glutamyltransferase inversely associated with serum antioxidants as a marker of oxidative stress? Free Rad Biol Med 2004; 37: 1018-1023. [CrossRef]
10. Tohidi M, Hatami M, Hadaegh F, Safarkhani M, Harati H, Azizi F. Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6-years follow-up of a population based cohort study. Lipids Health Dis 2010; 9: 6. [CrossRef]
11. Zhang L, Qiao Q, Laatikainen T, Söderberg S, Jousilahti P, Onat A, et al., for the DECODE Study Group. The impact of dyslipidaemia on incidence of coronary heart disease in Finns and Swedes with different categories of glucose tolerance. Diabetes Res Clin Pract 2011; 91: 406-412. [CrossRef]
12. Onat A, Hergenç G, Bulur S, Uǧur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol 2010; 142: 72-79. [CrossRef]
13. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism 2009; 58: 1393-1399. [CrossRef]
14. Onat A, Hergenç G. Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism 2011; 60: 499-512. [CrossRef]
15. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10. [CrossRef]
16. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al.; Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167. [CrossRef]
17. Onat A, Sari I, Hergenç G, Yazici M, Uyarel H, Can G, et al. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metabolism 2007; 56: 348-356. [CrossRef]
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497. [CrossRef]
19. Rose GA, Blackburn H, Gillum R F, Prineas RJ. Cardiovascular Survey Methods, 2nd edn. Geneva, World Health Organization, p 1982; 124-127.
20. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong B Y, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541-2549. [CrossRef]
21. Onat A, Can G, Çiçek G, Ayhan E, Doǧan Y, Kaya H. Fasting, non- fasting glucose and HDL dysfunction in risk of pre-diabetes, diabetes and coronary disease in non-diabetic adults. Acta Diabetol 2011 Jul 16 [Epub] doi: 10.1007/s00592-011-0313-x
22. Onat A, Sari I, Hergenç G, Yazici M, Uyarel H, Can G, et al. Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metabolism 2007; 56: 348-356. [CrossRef]
23. Corsetti J P, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 2006; 187: 191-197. [CrossRef]
24. Onat A, Can G, Kaya H, Hergenc ̧ G. "Atherogenic index of plasma" (log10 triglyceride/ high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events. J Clin Lipidol 2010; 4: 89-98. [CrossRef]
25. Onat A, Hergenç G, Can G, Kaya Z, Yüksel H. Serum Complement C3: a determinant of cardiometabolic risk, additive to metabolic syndrome, in middle-aged population. Metabolism 2010; 59: 628-634. [CrossRef]
26. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011; 412: 1171-1179. [CrossRef]
27. Hansel B, Giral P, Nobecourt E, Chantepie S, Bruckert E, Chapman MJ, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-49671. [CrossRef]
28. Libby P. Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. Circ Res 2007; 100: 299-301. [CrossRef]
29. Ting HJ, Stice J P, Schaff U Y, Hui DY, Rutledge JC, Knowlton AA, et al. Triglyceride-rich lipoproteins prime aortic endothelium for an enhanced inflammatory responses to TNF-α. Circ Res 2007; 100: 381-390. [CrossRef]
30. Onat A, Hergenç G, Ayhan E, Uǧur M, Kaya H, Tuncer M, et al. Serum apolipoprotein C-III in high-density lipoprotein: a key diabetogenic risk factor in Turks. Diabet Med 2009; 26: 981-988. [CrossRef]
31. de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, et al. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol 2006; 26: 1086-1093. [CrossRef]
32. Succurro E, Marini MA, Grembiale A, Lugarà M, Andreozzi F, Sciacqua A, et al. Differences in cardiovascular risk profile based on relationship between post-load plasma glucose and fasting plasma levels. Diabetes Metab Res Rev 2009; 25: 351-356. [CrossRef]
33. André P, Balkau B, Born C, Charles MA, Eschwege E. D.E.S.I.R. study group. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006; 49: 2599-2603. [CrossRef]
34. Mahley RW, Palaoǧlu KE, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36: 839-859.